-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $126

Benzinga·03/04/2026 17:46:40
Listen to the news
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $101 to $126.